drugset

drugset / Trial / NCT06149260

Subcutaneous Semaglutide in Systemic Scleroderma

NCT06149260 ↗

Phase 1 Unknown 10 enrolled Second Xiangya Hospital of Central South University

NaSingle-groupOpen-labelTreatment

Summary

This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis

Timeline

Start: 2024-02-29
Primary completion: 2024-08-29
Completion: 2024-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	0.5 mg	Subcutaneous

Indications